| Advances in risk classification and treatment strategies for neuroblastoma NR Pinto, MA Applebaum, SL Volchenboum, KK Matthay, WB London, ... Journal of clinical oncology 33 (27), 3008, 2015 | 816 | 2015 |
| Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of … B Geoerger, HJ Kang, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, ... The Lancet Oncology 21 (1), 121-133, 2020 | 246 | 2020 |
| Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis NA Vitanza, AJ Johnson, AL Wilson, C Brown, JK Yokoyama, A Künkele, ... Nature medicine 27 (9), 1544-1552, 2021 | 167 | 2021 |
| Clinically relevant genetic variations in drug metabolizing enzymes N Pinto, M Eileen Dolan Current drug metabolism 12 (5), 487-497, 2011 | 166 | 2011 |
| Rationale and design of the targeted agent and profiling utilization registry study PK Mangat, S Halabi, SS Bruinooge, E Garrett-Mayer, A Alva, ... JCO precision oncology 2, 1-14, 2018 | 163 | 2018 |
| Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study TO Henderson, S Bhatia, N Pinto, WB London, P McGrady, C Crotty, ... Journal of clinical oncology 29 (1), 76, 2011 | 153 | 2011 |
| A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized … P Pautier, A Floquet, L Gladieff, E Bompas, I Ray-Coquard, ... Annals of Oncology 24 (4), 1099-1104, 2013 | 149 | 2013 |
| Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy N Pinto, SM Ludeman, ME Dolan Pharmacogenomics 10 (12), 1897-1903, 2009 | 102 | 2009 |
| Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety NA Vitanza, AL Wilson, W Huang, K Seidel, C Brown, JA Gustafson, ... Cancer discovery 13 (1), 114-131, 2023 | 93 | 2023 |
| Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma F Ceppi, J Rivers, C Annesley, N Pinto, JR Park, C Lindgren, S Mgebroff, ... Transfusion 58 (6), 1414-1420, 2018 | 88 | 2018 |
| Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project MA Applebaum, Z Vaksman, SM Lee, EA Hungate, TO Henderson, ... European Journal of Cancer 72, 177-185, 2017 | 83 | 2017 |
| Second malignancies in patients with neuroblastoma: The effects of risk‐based therapy MA Applebaum, TO Henderson, SM Lee, N Pinto, SL Volchenboum, ... Pediatric blood & cancer 62 (1), 128-133, 2015 | 71 | 2015 |
| Decreased rates of severe CRS seen with early intervention strategies for CD19 CAR-T cell toxicity management R Gardner, KJ Leger, CE Annesley, C Summers, J Rivers, J Gust, ... Blood, The Journal of the American Society of Hematology 128 (22), 586-586, 2016 | 63 | 2016 |
| Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG) N Pinto, A Naranjo, E Hibbitts, SG Kreissman, MM Granger, MS Irwin, ... European Journal of Cancer 112, 66-79, 2019 | 55 | 2019 |
| Patterns of PD‐1, PD‐L1, and PD‐L2 expression in pediatric solid tumors N Pinto, JR Park, E Murphy, J Yearley, T McClanahan, L Annamalai, ... Pediatric blood & cancer 64 (11), e26613, 2017 | 54 | 2017 |
| Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms JL Davis, SO Vargas, ER Rudzinski, JM López Marti, K Janeway, ... Histopathology 76 (7), 1032-1041, 2020 | 48 | 2020 |
| Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: A report from NANT … SG DuBois, MM Granger, S Groshen, D Tsao-Wei, L Ji, A Shamirian, ... Journal of Clinical Oncology 39 (31), 3506, 2021 | 46 | 2021 |
| Diagnostic value of diffusion-weighted MRI for tumor characterization, differentiation and monitoring in pediatric patients with neuroblastic tumors H Neubauer, M Li, VR Müller, T Pabst, M Beer RöFo-Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden …, 2017 | 45 | 2017 |
| Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results KC Goldsmith, JR Park, K Kayser, J Malvar, YY Chi, SG Groshen, ... Nature medicine 29 (5), 1092-1102, 2023 | 42 | 2023 |
| Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial N Pinto, SG DuBois, A Marachelian, SJ Diede, A Taraseviciute, ... Pediatric blood & cancer 65 (7), e27023, 2018 | 36 | 2018 |
wendy londonProfessor of Pediatrics, Harvard Medical SchoolVerified email at childrens.harvard.edu
